{"doi":"10.1128/aac.00821-22","title":"A Plasmodium falciparum RING Finger E3 Ubiquitin Ligase Modifies the Roles of PfMDR1 and PfCRT in Parasite Drug Responses","abstract":"expression using glucosamine (GlcN). A Western blot analysis of the proteins from GlcN-treated pSLI-HA-NeoR-glmS-tagged (PfRFULg) parasites, relative to their wild-type (Dd2) controls, showed changes in the ubiquitination of numerous proteins. PfRFUL KD rendered the parasites more sensitive to multiple antimalarial drugs, including mefloquine, piperaquine, amodiaquine, and dihydroartemisinin. PfRFUL KD also decreased the protein level of the P. falciparum multiple drug resistance 1 protein (PfMDR1) and altered the ratio of two bands of the P. falciparum chloroquine resistance transporter (PfCRT), suggesting contributions to the changed drug responses by the altered ubiquitination of these two molecules. The inhibition of proteasomal protein degradation by epoxomicin increased the PfRFUL level, suggesting the degradation of PfRFUL by the proteasome pathways, whereas the inhibition of E3 ubiquitin ligase activities by JNJ26854165 reduced the PfRFUL level. This study reveals the potential mechanisms of PfRFUL in modifying the expression of drug transporters and their roles in parasite drug responses. PfRFUL could be a potential target for antimalarial drug development.","journal":"Antimicrobial Agents and Chemotherapy","year":2023,"id":358078,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9556,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":816031,"name":"Cui Zhang","orcid":"0000-0003-0886-6274","position":1,"is_corresponding":false},{"id":324083,"name":"Jian Wu","orcid":"0000-0001-5784-6160","position":2,"is_corresponding":false},{"id":324945,"name":"Yu‐Chih Peng","orcid":null,"position":3,"is_corresponding":false},{"id":324081,"name":"Xiao He","orcid":"0009-0004-9727-467X","position":4,"is_corresponding":false},{"id":324946,"name":"Keyla C. Tumas","orcid":null,"position":5,"is_corresponding":false},{"id":304395,"name":"Juliana M. Sá","orcid":"0000-0003-3813-8104","position":6,"is_corresponding":false},{"id":582606,"name":"Kristin D. Lane","orcid":"0000-0002-4352-0562","position":7,"is_corresponding":false},{"id":268257,"name":"Richard T. Eastman","orcid":"0000-0003-3580-380X","position":8,"is_corresponding":false},{"id":299010,"name":"David L. Narum","orcid":"0000-0003-3041-5402","position":9,"is_corresponding":false},{"id":304396,"name":"Thomas E. Wellems","orcid":"0000-0003-3899-8454","position":10,"is_corresponding":false},{"id":290725,"name":"Xin‐zhuan Su","orcid":"0000-0003-3246-3248","position":11,"is_corresponding":false},{"id":324085,"name":"Brajesh K. Singh","orcid":"0000-0002-2458-5950","position":0,"is_corresponding":true}],"reference_count":80,"raw_metadata":null,"created_at":"2026-07-19T01:13:43.629667Z","pmid":"36625569","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}